CEOCFO-Members Login


The Most Powerful Name In Corporate News and Information

Energy  |  Resources  |  Capital Goods |  Healthcare |  Financial  |  Technology  |  Communications


With FDA Approval for Most Wound Types and Medicare Reimbursement for their CellerateRX® Product, Wound Management Technologies, Inc. is in Position to Build on the Revenue Growth of 2010 that Tripled 2009 Numbers

Jr. Oil & Gas DBRM

Jr. Oil & Gas BEY

Jr. Oil & Gas MGWSF

Jr. Oil & Gas ATI

Jr. Oil & Gas FNR

Jr. Oil & Gas WPP

Jr. Oil & Gas XPL

Jr. Oil & Gas ATH

Oil Sands ATH

Light Sweet Crude XPL

Solar Energy CSKH

Renewable Energy CSKH

Wood Pellet VRD

Biofuels VRD

Wind Energy SENY

Clean Energy AEHI

Clean Technology SENY

Clean Technology SYMX

Hydrogen Generators DYA

Energy Tech DYA

Uranium ABE


Jr. Gold CCD

Jr. Gold AA

Jr. Gold WCX

Jr. Gold AEX

Jr. Gold ICX

Jr. Gold RCZ

Jr. Gold EXA

Jr. Gold FDN

Jr. Gold MAO

Jr. Gold EVG

Jr. Gold RYMM

Jr. Gold LAT

Jr. Exploration BKI

Paraguay Exploration LAT

Zinc SRZ

Precious Metals Extraction RYMM

Rare Earth QREF

Lithium LMR

Precious Metals AEX

Medical Device COO

Medical Device SFES

Medical Device CSDT

Drug Development WNDM

Drug Development APRI

Drug Development BPAX

Drug Development CTIX

Drug Development VICL

Drug Development ANX

Drug Development NBS

Drug Development LLTP

Drug Development BPTH

Development VICL

Women's Health BPAX

Health & Wellness BTX

Health & Wellness WELL

Cancer Detection CSDT

Cancer Research CTIX

Cancer Research ANX

Regenerative Medicine PROT

Adult Stem Cell Research & Storage NBS

Stem Cell PROT

Obesity Surgery SFES


 Autism Research CTIX

Commercial Banks EMPK

Commercial Banks ECBE


Insurance MIG

Business Development WELL

Business Banks AMBZ

Specialty Finance FSC

Specialty Finance GFIG

Specialty Finance FNR

Services GFIG




Technology - ESP

Technology SPA

Technology ANDR

Advanced Power DPW

Semiconducto LGL

Building Materials IBTGF

Fire Resistant Materials IBTGF

Business Services PRGX

Business Services CSPI

Business Services RKN

Business Services PMFI

Business Services AUXO

Business Services VSST

Business Services NSSI

Business Services GMT

Business Services ITEX

Business Services QIS

Canadian Resource LAT

Canadian Logistics GMT

Canadian Gold EVG

Canadian Oil ATH

Canadian Oil XPL

Canadian Biofuels VRD

Canadian Health
& Wellness BTX


Healthcare - Biotech Medical Devices
Wound Management Technologies, Inc. (WNDM-OTCPK; QB)
777 Main Street, Suite 3100
Fort Worth, TX 76102
Phone: 817-820-7077

Company Profile:

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage.

Deborah Jenkins Hutchinson - President / Director

Deborah's career, with over 30 years experience in the healthcare and technology sectors, is highlighted by a track record of successfully taking early development healthcare and biotech companies from concept to product development and finally to sales. She is an inventor and co-inventor with multiple US patents in pharmacy, telemedicine and other technical applications, and has led numerous initiatives in the healthcare technology arena. Hutchinson brings international business experience to WNDM, with past assignments in Europe, China, the Americas, and Asia. She is the past President of Healthcare Computer Corporation, past President of pH Solutions, Ltd., and served on numerous health industry boards and committees including the Intel Health Advisory Board and the Health Industry Business Communications Council Board (HIBCC). She is presently a director and advisor for Private Access, Inc.

Interview conducted by: Lynn Fosse, Senior Editor, CEOCFOinterviews.com, Published – May 6, 2011

CEOCFO: Ms. Jenkins Hutchinson, you have considerable history in the field, what attracted you to Wound Management Technologies?

Ms. Jenkins Hutchinson: Wound Management Technologies has very interesting biotech products and is developing additional healthcare technology products. These products are ready to be marketed worldwide, so what attracted me was the opportunity to take a lot of hard work and product preparation and commercialize the products.

CEOCFO: Would you tell us about the Wound Management Technologies product portfolio?

Ms. Jenkins Hutchinson: Wound Management Technologies primary focus is on a product called CellerateRX®, which is an activated advanced collagen product that is used in the wound-care market. The wound-care market is close to $5 billion worldwide for these types of products. It is a market that is growing because of the increase in diabetes and other conditions that require wound treatment products. Therefore, this is a large market space and we have a great product.

CEOCFO: What is the difference between CellerateRX and other products that are on the market?

Ms. Jenkins Hutchinson: What differentiates the Would Management Technologies CellerateRX product is that it is a patented product that fragments the collagen into tiny pieces. What that means is, when you apply it on a wound, your body immediately begins using it for its benefit. Other collagen products are native intact collagens that have to be broken down by your body before they can provide collagen to the wound site. Therefore, instead of taking a few days or weeks for your body to be able to avail itself of the collagen, the collagen works right away.

What is it that collagen does for the wound?

Ms. Jenkins Hutchinson: Collagen is a structural material that is produced by cells called fibroblasts. Within a wound, the collagen produced by the fibroblasts form granulation tissue to close the wound.

CEOCFO: Where are you in the process of developing and commercializing?

Ms. Jenkins Hutchinson: CellerateRX has Medicare reimbursement, and it is approved by the FDA for all wound types except third degree burns. So it has the foundation for marketing. Last year we had over three times the revenue of the year before. In 2011, we are saying that sales will increase six times that of 2010. The sales cycle for healthcare obviously has a bit of a timeframe to it because many sales are corporate sales to healthcare facility chains, hospitals, nursing homes, and other entities. We have over fifty deals in our opportunity pipeline; we have been closing those deals and making many announcements recently. We have had some big announcements in the last two weeks. We are selling through a variety of different channels, including retail and medical; everything from government VHA hospitals to major healthcare systems. Most recently, we announced a channel partner agreement to sell within the hospital and surgical market. Our strategy is a blend of direct sales and channel partner sales both in the US and internationally.

CEOCFO: How is CellerateRX applied?

Ms. Jenkins Hutchinson: CellerateRX comes in two forms, powder and gel. The powder is approximately 95% collagen, and the gel is approximately 65% collagen. They are used in different stages of wound repair. A deep wound may require powder which absorbs up to 30x its weight in drainage and creates a gelatinous biobarrier. As the wound goes through the healing process and gets drier, the gel will donate moisture to the wound bed and help keep it moist. Another benefit to the powder and gel is that they are ideal for tunneled or undermined wounds. CellerateRX gel can be put in a syringe for example and applied into a tunneled wound. Once the products are applied, they don’t have to be removed. They are biodegradable and biocompatible. So once you clean the wound site, you put the products in, you cover it up and leave it alone. Then during the next treatment you just put more product on top and recover the wound. It is easy to use.

CEOCFO: Has the medical community been looking for a better solution or is it just that they are going to be happy when they know you exist?

Ms. Jenkins Hutchinson: The medical community is always looking at wound care solutions, because it is such an enormous market with $5 billion of market space in just advanced wound-care. There are products on the market like Hyperbaric Chambers, and ultrasonic machines, so there are all kinds of technology driven wound-care devices. When you have something that is as simple as a powder or gel that has great efficacy, clearly it is something that is easier to use in most wound care settings. In addition, you do not have to transport the patient to a machine and you also have something that could easily be done by a patient at home in-between treatments.

CEOCFO: How do you reach the medical community?

Ms. Jenkins Hutchinson: We have some direct sales people that we hired last year that are directly calling on nurse practitioners, doctors, wound-care specialists, and nursing home chains. We are also working through the medical community with channel partners like Juventas, a group of Biomet distributors that we announced a deal with just last week, to sell into the medical surgical and hospital markets. McKesson, the largest pharmaceutical wholesaler in North America, carries the CellerateRX products. So, if a person goes to a medical tradeshow or hears about us through some sort of a promotion or is called by one of our sales people, they can contact a distributor and get the product delivered so they can use it and sell it.

CEOCFO: What about home use?

Ms. Jenkins Hutchinson: It absolutely works at home. One of the nice things about CellerateRX, particularly in home care or personal care, is that you do not have to have a prescription to buy the product. It is reimbursable under Medicare Part B with a physician’s order, so since it is not a prescription but is a medical device, you can buy it directly. We have an Internet distributor and we also have a distributor that sells through TV promotions. It is terrific for first-aid care in situations like injuries when a kid falls off a skateboard; or to treat road rash from a bicycle spill; or to stop the pain and treat a burn in the kitchen or from a barbeque grill. It is fabulous in all those situations.

CEOCFO: How do you convince people that it is really different?

Ms. Jenkins Hutchinson: Once they use it they get hooked. It is amazing! Even in the investment community people are saying, “I do not know if I believe this or not”. However, when they get a trial of this product, you hear back from them saying, “My mother in-law had a skin tear, wow; I burned myself on the grill, wow; my child skinned her knee, wow.” It really works!

CEOCFO: Where does Wound Management Technologies manufacture it products?

Ms. Jenkins Hutchinson: The products are manufactured in Pennsylvania under contract.

CEOCFO: Do you anticipate continuing to manufacture in the U.S., and do people care?

Ms. Jenkins Hutchinson: On some level people care, but we also have a growing international market to consider. Right now, we manufacture everything in the United States even for the international markets. At the end of the day, most people care more about the effectiveness of the product than where it is manufactured.

CEOCFO: Would you explain Wound Management Technologies’ geographic expansion?

Ms. Jenkins Hutchinson: Right now, we have distribution agreements throughout Central America that we have announced in the press. We have distribution and reimbursement agreements in South Africa and we have initiatives and distribution in the Middle East. We have a large distribution partner signed up for Italy and we are in the final stages of the CE certification necessary to distribute products there. There is a worldwide need for wound care products and it comes back to the prevalence of diabetes. Many countries are exhibiting increased rates of diabetes within their population; even to a greater extent than in the United States. Diabetics have wounds that need to be treated and CellerateRX is a great solution.

CEOCFO: What is the financial picture for Wound Management Technologies today?
Ms. Jenkins Hutchinson: The company has been emerging, so it has been continually raising money to supports its effort. We just announced in our President’s letter that we feel pretty solid for the short-term. We have some business deals that have created financial stability for the company and we did some small financings to get us to that point. We are very optimistic that we will be able to meet this year’s $6 million revenue forecast.

CEOCFO: Why should potential investors pay attention to Wound Management Technologies?

Ms. Jenkins Hutchinson: Investors should pay attention because the company is emerging. Wound Care Innovations, the marketer of CellerateRX, is our largest subsidiary within Wound Management Technologies. We acquired it in 2004 and a lot of time has been spent doing evidence-based studies and preparing for the marketing. The company’s sales were low during that time period. Now, investors are watching our news and seeing that what we say we are going to do, we are doing. It just proves that our plan is working. We will be cash flow positive and profitable in the next twelve to eighteen months. Besides that, we have two more products in the pipeline, so we are not just dependent on the CellerateRX wound care products.

CEOCFO: Would you tell us about the other Wound Management Technologies products?

Ms. Jenkins Hutchinson: We have a patent that we acquired in 2009 to produce resorbable bone wax and bone void filler products. It was just announced in the President’s letter that we are going through the final preparations to file the 10-Ks to get those products marketed later this year. We also have our healthcare technology group that focuses on secure communications between all parties involved in healthcare. They were part of a very interesting interoperability showcase at the largest healthcare technology show this February, HIMSS. They will be making more announcements this year as we create their commercialization strategy. Right now we forecast everything based on the CellerateRX product line, but those two other initiatives will begin to produce revenues by the end of the year.

CEOCFO: Has the investment community started to pay attention?

Ms. Jenkins Hutchinson: They have started to pay attention. We get lots of phone calls. We have an opt-in mail list that is getting a lot of traction. Every time we do a news release we hear from more new people. We have spoken at a number of investment meetings in the last year to update current shareholders and to spur interest from new ones. We have a speech coming up in June in New York at the One Med Forum biotech conference; we are just really beginning to reach out to investors.

CEOCFO: Final thoughts, what should people remember most when they read about Wound Management Technologies?
Ms. Jenkins Hutchinson: Wound Management Technologies is growing and hitting its milestones. It will be cash flow positive, and it will be profitable. We are doing what we said we were going to do and we believe Wound Management Technologies is going to emerge into quite a strong company.


Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.


WNDM-Print Version

Recent CEO Interviews, Collagen Wound Care Product, Resorbable Bone Wax for , healthcare data storage companies, Biotechnology, Biotech Stocks, Healthcare Stock, powder and gel wound care products for diabetics, CellerateRX, wound treatment for diabetics, wound care for diabetes, Biotech Stock, Healthcare, Biotechnology, Biopharmaceuticals, Pharmaceutical,
Drug Manufacturers, Medical Instruments & Supplies, Medical Devices, Cancer Therapies & Treatment Stock

More headlines.....

Pharmaceutical Company Cellceutix Corp. Announces A Novel Drug For Treating Autism; Cellceutix Advances Towards Clinical Trials With Its Flagship Compound For Resistant Cancers

Nabi Biopharmaceuticals Is Offering Hope To People Addicted To Cigarettes With Their Smoking Cessation Vaccine, NicVAX®, That Stimulates The Body’s Immune System To Produce Antibodies That Help Protect Against The Addictive Properties Of Nicotine Thereby Helping Them Quit Smoking

RXi Pharmaceuticals Corporation’s New President And CEO, Noah D. Beerman Has The Company Focused On Identifying The Best Opportunities For Their RNAi Technology, Selecting Specific Development Candidates And Formalizing Their Relationships With Corporate Partners


Bio-Solutions Corp. Is Focused On Two Large Market Areas With Their NutraAnimal™ Organic Feed Supplement For The Poultry Industry And Their GreenEx™ Biological Insecticide To Help Combat Mosquitoes That Carry Deadly Diseases Such As Malaria

With The Last Drug Approved For Painful Bladder Syndrome/Interstitial Cystitis Thirteen Years Ago Often Taking 6 Months To Provide A Benefit, Urigen Pharmaceuticals, Inc. Is Bringing Hope With Their URG101 That Provides Initial Relief In A Matter Of Minutes Now In Phase II Clinical Studies

With Four Key Programs Ongoing Including Immunotherapy Allovectin-7® For Melanoma In Phase 3 Clinical Studies That Has Shown To Be Well Tolerated With Little Side-Effects, Vical Incorporated Is Well Positioned For Future Growth

With Four Pain Control Products (Remoxy™, POSIDUR™, ELADUR™ And A Sufentanil Patch) In Advanced Clinical Studies, And Partners In Place To Help Bring Them To Market, DURECT Corporation Is Well Positioned For Future Growth

Using A Different Approach Provectus Pharmaceuticals, Inc. Has Been Able To Develop Small Molecule Drugs For Cancer And Psoriasis That Will Target The Diseased Cells And Leave The Normal Cells Untouched


ReBuilder Medical Technologies, Inc. Has Invented, Manufactured And Distributes Worldwide, An Electronic Medical Device Designed To Overcome The Pain Of Diabetic Peripheral Neuropathy As Well As Arthritis


NeoStem, Inc.
Print Version

Become A Member!

Access thousands of full-text Public Company CEO & CFO Interviews!

You Get - the future plans for your stock investment - Financing, Growth Strategy, Company Contact Information and more!

Stay ahead of the pack!

Become a CEOCFO Member
Now! Only $9.99

*One year subscription!*




Wound Management Technologies primary focus is on a product called CellerateRX®, which is an activated advanced collagen product that is used in the wound-care market. The wound-care market is close to $5 billion worldwide for these types of products. It is a market that is growing because of diabetes and other conditions that have a need for wound treatment products. Therefore, this is a large market space and we have a great product. - Ms. Deborah Jenkins Hutchinson

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.

Jr. Oil & Gas DBRM, Jr. Oil & Gas BEY, Jr. Oil & Gas MGWSF, Jr. Oil & Gas ATI, Jr. Oil & Gas FNR, Jr. Oil & Gas WPP, Jr. Oil & Gas XPL, Jr. Oil & Gas ATH, Oil Sands ATH, Light Sweet Crude XPL, Solar Energy CSKH, Renewable Energy CSKH, Wood Pellet VRD, Biofuels VRD, Wind Energy SENY, Clean Energy AEHI, Clean Technology SENY, Clean Technology SYMX, Hydrogen Generators DYA, Energy Tech DYA, Uranium ABE, Jr. Gold CCD, Jr. Gold AA, Jr. Gold WCX, Jr. Gold AEX, Jr. Gold ICX, Jr. Gold RCZ, Jr. Gold EXA, Jr. Gold FDN, Jr. Gold MAO, Jr. Gold EVG, Jr. Gold RYMM, Jr. Gold LAT, Paraguay Exploration LAT, Zinc SRZ, Precious Metals Extraction RYMM, Rare Earth ORE, Lithium LMR, Precious Metals AEX, Medical Device COO, Medical Device SFES, Medical Device CSDT, Drug Development APRI, Drug Development BPAX, Drug Development CTIX, Drug Development VICL, Drug Development ANX, Drug Development NBS, Drug Development LLTP, Drug Development BPTH, Vaccine Development VICL, Women's Health BPAX, Health & Wellness BTX, Health & Wellness WELL, Cancer Detection CSDT, Cancer Research CTIX, Cancer Research ANX, Regenerative Medicine PROT, Adult Stem Cell Research & Storage NBS, Stem Cell PROT, Obesity Surgery SFES, GERD Surgery SFES, Autism Research CTIX, Insurance MIG, Business Development WELL, Business Banks AMBZ, Commercial Banks ECBE, Specialty Finance FSC, Specialty Finance GFIG, Specialty Finance FNR, Brokerage Services GFIG, REIT TWO, REIT BDN, Technology SPA, Technology ANDR, Advanced Power DPW, Semiconducto LGL, Building Materials IBTGF, Fire Resistant Materials IBTGF, Business Services PRGX, Business Services CSPI, Business Services RKN, Business Services PMFI, Business Services AUXO, Business Services VSST, Business Services NSSI, Business Services GMT, Business Services ITEX, Business Services QIS